On Demand 2023 Sunday PM General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Primary Prevention Strategies for Asthma
  • ProCon - Skin Testing vs Serum Testing for the Diagnosis of Venom Allergy
  • Jeopardy - What's That Rash?
  • Introductory Course in Rhinolaryngoscopy
  • Allergen Immunotherapy in Your Practice - Are You Up to Date with the Current Parameters?
  • An Ounce of Prevention in Food Allergy
  • The Ever-Changing Landscape of COVID-19

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Define basic dermatology terms.
  • Differentiate between skin lesions that have a similar appearance.
  • Develop appropriate treatment plans.
  • Identify the relative merits of venom skin and serum testing.
  • Indicate the relative merits of component venom testing.
  • Describe the major anatomical findings in the upper airway.
  • Identify normal and abnormal anatomy, disease presentations and post-op findings.
  • Appraise indications for use of the rhinoscope in the allergist's office.
  • Extrapolate the role that microbial exposures (including infection and colonization) play in the development of asthma.
  • Calculate the role that maternal health and exposures, as well as childhood obesity and diet, play in the development of asthma.
  • Review the evidence for airborne/inhalational exposures influencing the development of asthma, as well as medication that may have a role in asthma prevention.
  • Analyze available data on SCIT and SLIT and discuss risks of both therapies.
  • Summarize current recommendations on patient selection and allergen dosing in allergy immunotherapy.
  • Describe available tools to help identify efficacy, safety, and quality of life outcomes in patients on allergy immunotherapy.
  • Describe the role of early food introduction for allergenic foods and how to provide practical advice for families.
  • Discuss the role of the skin barrier in food allergy development and prevention.
  • Highlight future approaches in preventing food allergy.
  • Summarize the latest updates in management of outpatient COVID.
  • Distinguish manifestations of long COVID and provide an update on the science of this complicated condition.
  • Appraise recent trends in pediatric and adult vaccination, and how they may relate to the COVID-19 pandemic.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance
  • 11.00 CBRN
Course opens: 
12/01/2023
Course expires: 
11/30/2026
Part of: 
On Demand ACAAI 2023 Annual Scientific Meeting General Sessions
Rating: 
0

Jeremy S. Katcher, MD, FACAAI  
Justin C. Greiwe, MD, FACAAI  
Andrew L. Kau, MD, PhD  
Thomas AE Platts-Mills, MD, PhD, FACAAI  
Wanda Phipatanakul, MD, MS, FACAAI
James M. Tracy, DO, FACAAI  
David B.K. Golden, MDCM, FACAAI  
Karla Adams, MD, FACAAI
David R. Stukus, MD, FACAAI  
Kelly M. Maples, MD, FACAAI  
Luz S. Fonacier, MD, FACAAI  
Anitha Shrikhande, MD  
Andrew Alexis, MD, MPH
Jerald W. Koepke, MD, FACAAI  
Seong H. Cho, MD, FACAAI
Robert J. Szalewski, MD  
Nicole E. Barberis, MD  
Maureen M. Petersen, MD, FACAAI  
Anne K. Ellis, MD, MSc, FACAAI  
Dennis Keith Ledford, MD, FACAAI
Robert Sporter, MD, FACAAI
Jing Yi (Jenny) Sun, MD  
Elissa Michele Abrams, MD MPH FRCPC  
Christina E. Ciaccio, MD, MSc, FACAAI  
Helen A. Brough, MD PhD FAAAAI
Niraj C. Patel, MD, MS, FACAAI  
Joseph P. Forester, DO, FACAAI  
Syed Shahzad Mustafa, MD, FACAAI 
Purvi S. Parikh, MD, FACAAI  
Paul V. Williams, MD, FACAAI

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Attendance
  • 11.00 CBRN
Please login or create an account to take this course.